Association of XPD and XRCC1 Genetic Polymorphisms with Hepatocellular Carcinoma Risk

  • Guo, Lian-Yi (Department of Gastroenterology, The First Affiliated Hospital, Liaoning Medical University) ;
  • Jin, Xu-Peng (Liaoning Medical University) ;
  • Niu, Wei (Department of Gastroenterology, The First Affiliated Hospital, Liaoning Medical University) ;
  • Li, Xiao-Fei (Department of Gastroenterology, The First Affiliated Hospital, Liaoning Medical University) ;
  • Liu, Bao-Hai (Department of Gastroenterology, The First Affiliated Hospital, Liaoning Medical University) ;
  • Wang, Yu-Lin (Hepatobiliary, the Affiliated Hospital, the Armed Police College of Medicine)
  • Published : 2012.09.30


Aim: XRCC1 and XPD are two major repair genes involved in nucleotide excision repair (NER), which is reported to be associated with risk of several cancers. We explored the association of XRCC1 and XPD polymorphisms with the risk of HCC. Methods: A total of 410 cases with HCC and 410 health controls were collected. XRCC1 Arg194Trp, XRCC1 Arg399Gln, XPD Lys751Gln and XPD Asp312Asn genotyping was performed by duplex polymerase-chain-reaction with the confronting-two-pair primer (PCR-CTPP) method. Results: XRCC1 194Trp/Trp was strongly significantly associated with an increased risk of HCC cancer when compared with the wide-type genotype (OR=2.26, 95% CI=(1.23-5.38). Individuals carrying the XRCC1 399Gln/Gln showed increased risk of HCC (OR=1.74, 95%CI=1.06-2.74). The XPD 751Gln/Gln and Gln allele genotype were associated with strong elevated susceptibility to HCC (OR=3.51 and 1.42, respectively). Conclusion: These results suggest that polymorphisms in XRCC1 and XPD may have functional significance in risk of HCC.


  1. Basso D, Navaglia F, Fogar P, et al (2007). DNA repair pathways and mitochondrial DNA mutations in gastrointestinal carcinogenesis. Clin Chim Acta, 381, 50-5.
  2. Benhamou S, Sarasin A (2002). ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis, 17, 463-9.
  3. Bowen DG, Walker CM (2005). Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature, 436, 946-52.
  4. Bradbury PA, Kulke MH, Heist RS, et al (2009). Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics, 19, 613-25.
  5. Chacko P, Rajan B, Joseph T, et al (2005). Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to breast cancer. Breast Cancer Res Treat, 89, 15-21.
  6. Cui Z, Yin Z, Li X, et al (2012). Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis. BMC Cancer, 12, 71.
  7. International Agency for Research on Cancer (2008). Liver cancer incidence and mortality worldwide in 2008. 2011;
  8. Kiran M, Saxena R, Chawla YK, et al (2009). Polymorphism of DNA repair gene XRCC1 and hepatitis-related hepatocellular carcinoma risk in Indian population. Mol Cell Biochem, 327, 7-13.
  9. Lavanchy D(2004). Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures. J Viral Hepat, 11, 97-107.
  10. Li QW, Lu CR, Ye M, et al (2012). Evaluation of DNA repair gene XRCC1 polymorphism in prediction and prognosis of hepatocellular carcinoma risk. Asian Pac J Cancer Prev, 13, 191-4.
  11. Liu Y, Chen H, Chen L, et al (2012). Prediction of genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 in the survival of colorectal cancer receiving chemotherapy in the Chinese population. Hepatogastroenterology, 59, 977-80.
  12. Long XD, Ma Y, Zhou YF, et al (2009). XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk. BMC Cancer, 9, 400.
  13. Yin M, Yan J, Martinez-Balibrea E, et al(2011). ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res, 17, 1632-40.
  14. Mandal RK, Gangwar R, Kapoor R, et al (2012). Polymorphisms in base-excision & nucleotide-excision repair genes & prostate cancer risk in north Indian population. Indian J Med Res, 135, 64-71.
  15. Manuguerra M, Saletta F, Karagas MR, et al (2006). XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review. Am J Epidemiol, 164, 297-302.
  16. Pan HZ, Liang J, Yu Z, et al(2011). Polymorphism of DNA repair gene XRCC1 and hepatocellular carcinoma risk in Chinese population. Asian Pac J Cancer Prev, 12, 2947-50.
  17. Ronen A, Glickman BW (2001). Human DNA repair genes. Environ Mol Mutagen, 37, 241-83.
  18. Rzeszowska-Wolny J, Polanska J, Pietrowska M, et al (2005). Influence of polymorphisms in DNA repair genes XPD, XRCC1 and MGMT on DNA damage induced by gamma radiation and its repair in lymphocytes in vitro. Radiat Res, 164, 132-40.
  19. Shen MR, Jones IM, Mohrenweiser H (1998). Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res, 58, 604-8.
  20. Slyskova J, Naccarati A, Pardini B, et al (2012). Differences in nucleotide excision repair capacity between newly diagnosed colorectal cancer patients and healthy controls. Mutagenesis, 27, 225-32.
  21. Smith TR, Miller MS, Lohman K, et al (2003). Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer. Cancer Lett, 190, 183-90.
  22. Spitz MR, Wu X, Wang Y, et al (2001). Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res, 61, 1354-7.
  23. Thompson LH, Brookman KW, Jones NJ, et al (1990). Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatid exchange. Mol Cell Biol, 10, 6160-71.
  24. Tudek B (2007). Base excision repair modulation as a risk factor for human cancers. Mol Aspects Med, 28, 258-75.
  25. Yin J, Wang C, Liang D, et al (2012). No evidence of association between the synonymous polymorphisms in XRCC1 and ERCC2 and breast cancer susceptibility among nonsmoking Chinese. Gene, 503, 118-22.
  26. Zhang L, Ruan Z, Hong Q, et al (2012). Single nucleotide polymorphisms in DNA repair genes and risk of cervical cancer: A case-control study. Oncol Lett, 3, 351-62.

Cited by

  1. The XRCC1 Arg399Gln Genetic Polymorphism Contributes to Hepatocellular Carcinoma Susceptibility: An Updated Meta-analysis vol.14, pp.10, 2013,
  2. XPD Lys751Gln and Asp312Asn Polymorphisms and Susceptibility to Skin Cancer: A Meta-Analysis of 17 Case-control Studies vol.15, pp.16, 2014,
  3. An Updated Meta-analysis Between the Association of XRCC1 Arg399Gln Polymorphism and Hepatocellular Carcinoma Risk vol.15, pp.7, 2014,
  4. Genetic polymorphisms of XRCC1 gene and susceptibility to hepatocellular carcinoma in Chinese population vol.31, pp.4, 2014,
  5. A pooled analysis of the ERCC2 Asp312Asn polymorphism and esophageal cancer susceptibility vol.35, pp.4, 2014,
  6. Association Between XPD Lys751Gln and Asp312Asn Polymorphisms and Hepatocellular Carcinoma Risk vol.93, pp.29, 2014,
  7. Association of XRCC1 Arg399Gln Polymorphism with Colorectal Cancer Risk: A HuGE Meta Analysis of 35 Studies vol.16, pp.8, 2015,
  8. DNA repair genes XPD and XRCC1 polymorphisms and risk of end-stage renal disease in Egyptian population vol.37, pp.1, 2015,
  9. XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis of 11 case-control studies in an Asian population vol.9, pp.6, 2015,
  10. The association of six non-synonymous variants in three DNA repair genes with hepatocellular carcinoma risk: a meta-analysis vol.20, pp.11, 2016,
  11. DNA repair gene XRCC1 Arg194Trp polymorphism and susceptibility to hepatocellular carcinoma: A meta-analysis vol.8, pp.4, 2014,
  12. Associations between three XRCC1 polymorphisms and hepatocellular carcinoma risk: A meta-analysis of case-control studies vol.13, pp.11, 2018,
  13. XPD suppresses cell proliferation and migration via miR-29a-3p-Mdm2/PDGF-B axis in HCC vol.9, pp.1, 2019,